299P - Furmonertinib as adjuvant therapy in EGFR-mutated non-small cell lung cancer following radical lung cancer surgery

Background

Furmonertinib (AST2818) is a novel promising third-generation EGFR tyrosine kinase inhibitor (TKI) that targets both EGFR sensitive mutations and T790M mutation. Furmonertinib has shown encouraging efficacy and good tolerability in advanced Non–Small-Cell Lung Cancer (NSCLC) in previous clinical trials, especially in patients with CNS metastasis. Here, we investigated the efficacy and safety of furmonertinib as adjuvant therapy in postoperative EGFR-mutated NSCLC patients.

Methods

Patients who underwent radical lung cancer surgery with EGFR mutations were enrolled and received furmonertinib 80mg daily. The adjuvant therapy time (up to 3 years) depended on patients’ pathologic stage and physical conditions. We evaluated the disease-free survival (DFS), safety, tolerability, and the efficacy of furmonertinib in patients with multiple ground-glass opacity (mGGO) lesions.

Results

This study retrospectively analyzed 106 patients who were pathologically confirmed adenocarcinoma, EGFR mutation positive (exon 19 deletion, L858R, exon20 ins or G719A), stage ⅠA2–ⅢB NSCLC. All patients were followed at least 6 months, and 47 patients have been followed up for over 1 year, median follow-up was 11.0 months. By the cut-off date of July 1, 2022, all patients were alive and there was no tumor recurrence. During furmonertinib treatment, 33 patients (33/106, 31.1%) had treatment-related adverse events (TRAEs), grade≥3 TRAEs occurred in 2 patients (2/106, 1.9%). The most common TRAEs were rash (19/106, 17.9%), diarrhea (9/106, 8.5%), fatigue (6/106, 5.7%) and transaminase elevation (5/106, 4.7%). 1 patient (1/106,0.9%) discontinued therapy due to adverse event. The therapeutic effects of furmonertinib in patients with mGGO lesions were also evaluated in this study. Among 35 patients (35/106, 33.0%) who have mGGO lesions after surgery, lesions shrinkage were observed in 17 patients (17/35, 48.6%).

Conclusions

Furmonertinib showed good efficacy as adjuvant therapy in EGFR-muteted NSCLC patients who underwent radical lung cancer surgery, along with an acceptable safety profile without new signals. Furmonertinib also had potential therapeutic efficacy in patients with mGGO lesions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.